MPAN — Mitochondrial Membrane Protein-Associated Neurodegeneration

Migration, Crosslink

📖

MPAN — Mitochondrial Membrane Protein-Associated Neurodegeneration

active

wiki page Created: 2026-04-02T07:20:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-mitochondrial-membrane-p

📖 Wiki Page

mechanism2002 wordssynced 2026-04-02

MPAN — Mitochondrial Membrane Protein-Associated Neurodegeneration

Overview

MPAN (Mitochondrial Membrane Protein-Associated Neurodegeneration, Mitochondrial CoA Synthesis Dysfunction) is the third most common NBIA disorder, caused by autosomal recessive mutations in the [COASY](/entities/coasy) gene (coenzyme A synthetase) or less commonly [MTOR](/entities/mtor). The disorder presents in adolescence or early adulthood with progressive dystonia, parkinsonism, and cognitive decline. MPAN is distinguished by mitochondrial respiratory chain dysfunction and iron-sulfur cluster assembly defects alongside the characteristic brain iron accumulation[@dusi2022].

Genetics and Inheritance

| Feature | Detail |
|---------|--------|
| Gene | COASY (coenzyme A synthetase) |
| Inheritance | Autosomal recessive |
| Mechanism | Loss-of-function mutations |
| Allelic disorder | DOORS syndrome (some COASY variants) |
| Protein | CoA synthetase (bifunctional enzyme: pantothenate kinase + CoA synthetase domains) |

COASY encodes a bifunctional enzyme that catalyzes the final two steps of coenzyme A biosynthesis: (1) conversion of phosphopantetheine to dephospho-CoA, and (2) ATP-dependent phosphorylation of dephospho-CoA to CoA[@dusi2022]. Unlike PANK2 (which catalyzes step 1), COASY mutations cause deficiency in the final step of the pathway, creating a distinct biochemical phenotype from PKAN.

Molecular Mechanism

```mermaid
flowchart TD
A["COASY Biallelic Mutation"] --> B["Loss of CoA Synthetase Activity"]

...

MPAN — Mitochondrial Membrane Protein-Associated Neurodegeneration

Overview

MPAN (Mitochondrial Membrane Protein-Associated Neurodegeneration, Mitochondrial CoA Synthesis Dysfunction) is the third most common NBIA disorder, caused by autosomal recessive mutations in the [COASY](/entities/coasy) gene (coenzyme A synthetase) or less commonly [MTOR](/entities/mtor). The disorder presents in adolescence or early adulthood with progressive dystonia, parkinsonism, and cognitive decline. MPAN is distinguished by mitochondrial respiratory chain dysfunction and iron-sulfur cluster assembly defects alongside the characteristic brain iron accumulation[@dusi2022].

Genetics and Inheritance

| Feature | Detail |
|---------|--------|
| Gene | COASY (coenzyme A synthetase) |
| Inheritance | Autosomal recessive |
| Mechanism | Loss-of-function mutations |
| Allelic disorder | DOORS syndrome (some COASY variants) |
| Protein | CoA synthetase (bifunctional enzyme: pantothenate kinase + CoA synthetase domains) |

COASY encodes a bifunctional enzyme that catalyzes the final two steps of coenzyme A biosynthesis: (1) conversion of phosphopantetheine to dephospho-CoA, and (2) ATP-dependent phosphorylation of dephospho-CoA to CoA[@dusi2022]. Unlike PANK2 (which catalyzes step 1), COASY mutations cause deficiency in the final step of the pathway, creating a distinct biochemical phenotype from PKAN.

Molecular Mechanism

Mermaid diagram (expand to render)

CoA Metabolism Defect

CoA is essential for:

Mitochondrial energy metabolism (citric acid cycle, fatty acid oxidation)
Acetylation reactions (protein function regulation, histone acetylation)
Synthesis of phospholipids and neural membranes
Mitochondrial protein import

The COASY enzyme catalyzes the final step of CoA biosynthesis, making it indispensable for cellular CoA homeostasis. Loss of function causes 30-70% reduction in cellular CoA depending on tissue[@dusi2022].

Mitochondrial Respiratory Chain Dysfunction

CoA deficiency impairs:

Complex I and II function (require CoA for electron transfer)
Citric acid cycle flux (multiple CoA-dependent dehydrogenases)
Fatty acid beta-oxidation (acyl-CoA dehydrogenase step)
The combined deficit creates a bioenergetic crisis in high-energy-demand neurons of the basal ganglia.

Iron-Sulfur Cluster Assembly

Iron-sulfur (Fe-S) clusters are essential cofactors for:

Complex I, II, and III electron transport proteins
DNA repair enzymes (XPD, glycosylases)
Metabolic enzymes (aconitase, ferredoxin)

CoA deficiency disrupts the mitochondrial Fe-S cluster assembly machinery. This explains why MPAN has more prominent mitochondrial dysfunction than PKAN, and why neurons with high metabolic demands are preferentially affected.

Clinical Presentation

| Feature | MPAN Characteristics |
|---------|----------------------|
| Age of onset | Adolescence (10-20 years), occasionally earlier or later |
| Initial symptoms | Gait difficulties, dystonia, clumsiness |
| Core phenotype | Dystonia-parkinsonism (often mixed) |
| Progression | Slowly progressive over decades |
| Cognitive decline | Variable, typically mild-to-moderate |
| Psychiatric symptoms | Common (personality change, depression, OCD features) |
| MRI "eye of the tiger" | Rare or absent (unlike PKAN) |
| Optic atrophy | May occur |
| Seizures | Less common than in BPAN |

Distinctive from PKAN

Later onset than classic PKAN
Less prominent eye of the tiger sign on MRI
More prominent psychiatric features
Slower progression
No pantothenate supplementation response expected

MRI and Diagnostic Findings

| Finding | MPAN Specifics |
|---------|----------------|
| Iron accumulation | Globus pallidus and substantia nigra (SN) |
| Eye of the tiger sign | Usually absent or mild |
| T2 signal changes | SWI hypointensity in GP/SN |
| White matter changes | May be present |
| Atrophy | Progressive caudate and putaminal atrophy |

Therapeutic Approaches

Current Approaches

| Approach | Status | Evidence |
|----------|--------|----------|
| CoA supplementation | Theoretical | CoA crosses BBB poorly; pantetheine/pantethine more viable |
| Pantethine (vitamin B5 derivative) | Experimental | Bypasses PANK2 defect; may partially compensate for COASY loss |
| Iron chelation | Case-by-case | If iron-mediated toxicity predominates |
| DBS (deep brain stimulation) | Used for dystonia | Case reports show benefit for severe dystonia |
| Physical/occupational therapy | Supportive | Maintains function |
| Psychiatric management | Symptomatic | SSRI/SNRI for depression/anxiety |

Emerging Research

Gene therapy: AAV-mediated COASY delivery (preclinical)
Small molecule CoA prodrugs: Designed to cross BBB
Mitochondrial biogenesis stimulants: PGC-1alpha agonists to compensate for respiratory chain deficit
Iron chelators with CNS penetration: Deferiprone trials in NBIA subtypes

Cross-Links

[NBIA Overview](/diseases/nbia)
[PKAN Pathway](/mechanisms/pkan-neurodegeneration-pathway)
[Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction-comparison)
[Dystonia Mechanisms](/mechanisms/dystonia-mechanisms)
[COASY Gene](/entities/coasy) (when created)
[MTOR Gene](/entities/mtor) (when created)

CoA Biosynthesis Pathway

Complete Pathway Overview

CoA biosynthesis involves five enzymatic steps, with COASY catalyzing the final two:

Mermaid diagram (expand to render)

COASY Enzyme Function

COASY is a bifunctional enzyme containing two domains:

| Domain | Function | Reaction |
|--------|----------|----------|
| Phosphopantetheine adenylyltransferase (PPAT) | First half of reaction | 4'-phosphopantetheine + ATP → dephospho-CoA + PPi |
| Dephospho-CoA kinase (DPCK) | Second half of reaction | dephospho-CoA + ATP → CoA + ADP |

The reaction mechanism:

4'-phosphopantetheine binds to PPAT domain

ATP donates AMP moiety, forming dephospho-CoA

DPCK domain catalyzes phosphate transfer from ATP

CoA is released for use in cellular metabolism[@krueger2012]

Mitochondrial CoA Pools

CoA exists in multiple cellular pools:

| Pool | Location | Function | % of Total |
|------|----------|----------|------------|
| Mitochondrial | Matrix | Energy metabolism, TCA | 60-80% |
| Cytosolic | Cytosol | Biosynthetic reactions | 10-20% |
| Peroxisomal | Peroxisome | Fatty acid oxidation | 5-10% |

In MPAN, the mitochondrial pool is preferentially affected due to COASY's mitochondrial localization, explaining the prominent respiratory chain dysfunction[@marti2023].

Clinical Presentation

| Feature | MPAN Characteristics |
|---------|----------------------|
| Age of onset | Adolescence (10-20 years), occasionally earlier or later |
| Initial symptoms | Gait difficulties, dystonia, clumsiness |
| Core phenotype | Dystonia-parkinsonism (often mixed) |
| Progression | Slowly progressive over decades |
| Cognitive decline | Variable, typically mild-to-moderate |
| Psychiatric symptoms | Common (personality change, depression, OCD features) |
| MRI "eye of the tiger" | Rare or absent (unlike PKAN) |
| Optic atrophy | May occur |
| Seizures | Less common than in BPAN |

Distinctive from PKAN

Later onset than classic PKAN
Less prominent eye of the tiger sign on MRI
More prominent psychiatric features
Slower progression
No pantothenate supplementation response expected

Disease Progression

Longitudinal studies show[@schneider2023]:

| Stage | Age | Features |
|-------|-----|----------|
| Preclinical | <10 years | Often asymptomatic, may have subtle findings |
| Early | 10-15 years | Gait disturbance, mild dystonia |
| Established | 15-25 years | Prominent dystonia-parkinsonism, cognitive changes |
| Advanced | >25 years | Severe motor disability, possible wheelchair use |

MRI and Diagnostic Findings

| Finding | MPAN Specifics |
|---------|----------------|
| Iron accumulation | Globus pallidus and substantia nigra (SN) |
| Eye of the tiger sign | Usually absent or mild |
| T2 signal changes | SWI hypointensity in GP/SN |
| White matter changes | May be present |
| Atrophy | Progressive caudate and putaminal atrophy |

Diagnostic Approach

Clinical suspicion: Adolescent-onset dystonia with psychiatric features

MRI: SWI for iron deposition in GP/SN

Genetic testing: COASY sequencing

Biochemical studies: Plasma/urine acylcarnitine analysis (may be normal)

Differential Diagnosis

| Condition | Distinguishing Features |
|-----------|------------------------|
| PKAN | Earlier onset, prominent eye of the tiger, pantothenate responsive |
| PLAN | Earlier onset, more severe phenotype |
| BPAN | Earlier onset, developmental delay, seizures |
| Kufor-Rakeb | Adult onset, levodopa responsive |
| PKAN-like (PLAN) | PANK2 negative but similar phenotype |

Therapeutic Approaches

Current Approaches

| Approach | Status | Evidence |
|----------|--------|----------|
| CoA supplementation | Theoretical | CoA crosses BBB poorly; pantetheine/pantethine more viable |
| Pantethine (vitamin B5 derivative) | Experimental | Bypasses PANK2 defect; may partially compensate for COASY loss |
| Iron chelation | Case-by-case | If iron-mediated toxicity predominates |
| DBS (deep brain stimulation) | Used for dystonia | Case reports show benefit for severe dystonia |
| Physical/occupational therapy | Supportive | Maintains function |
| Psychiatric management | Symptomatic | SSRI/SNRI for depression/anxiety |

Pantethine Rationale

Pantethine (the stable disulfide of pantetheine) can bypass both PANK2 and COASY defects:

Mermaid diagram (expand to render)

Preliminary studies suggest modest benefit in some patients["@fourel2023"].

Deep Brain Stimulation

DBS has been used successfully in MPAN patients with severe dystonia[@giron2024]:

Target: GPi (globus pallidus interna)
Outcomes: 40-70% improvement in dystonia scores
Complications: Similar to other NBIA subtypes
Considerations: Earlier intervention may provide better outcomes

Emerging Research

Gene therapy: AAV-mediated COASY delivery (preclinical)[@zhou2024]
Small molecule CoA prodrugs: Designed to cross BBB
Mitochondrial biogenesis stimulants: PGC-1alpha agonists to compensate for respiratory chain deficit
Iron chelators with CNS penetration: Deferiprone trials in NBIA subtypes

Research Directions

Clinical Trials

Currently, no MPAN-specific clinical trials are actively recruiting. However:

NBIA natural history studies include MPAN patients
Biomarker studies are ongoing
Patient registries are being expanded

Biomarker Development

Priority biomarkers for MPAN include:

| Biomarker | Source | Purpose |
|-----------|--------|---------|
| CoA levels | Plasma/CSF | Disease monitoring |
| Acylcarnitines | Plasma | Metabolic status |
| Neurofilament light | Serum/CSF | Neuronal damage |
| Ferritin | Serum | Iron burden |

Gene Therapy Approaches

Preclinical gene therapy for MPAN uses:

AAV vectors: Deliver functional COASY gene

Target cells: Neurons and glia

Delivery: Intracerebral or intravenous

Challenge: Achieving sufficient expression in basal ganglia

Current status: Research phase, with studies in mouse models showing promise[@zhou2024].

[Dusi S, et al., COASY Mutations Cause MPAN Am J Hum Genet (2022)](https://pubmed.ncbi.nlm.nih.gov/35063126)

[Kruer MC, et al., NBIA Spectrum Disorders Nat Rev Neurol (2022)](https://pubmed.ncbi.nlm.nih.gov/35710885)

[Gregory A, et al., Iron Metabolism in NBIA Brain (2021)](https://pubmed.ncbi.nlm.nih.gov/33941381)

[Hoglinger GU, et al., Consensus clinical management guideline for NBIA subtypes Mov Disord (2021)](https://pubmed.ncbi.nlm.nih.gov/34128564)

[Bolognino F, et al., COASY-associated neurodegeneration: expanding the phenotypic spectrum Neurogenetics (2023)](https://pubmed.ncbi.nlm.nih.gov/36795123)

[Krueger MC, et al., Coenzyme A biosynthesis and disease J Inherit Metab Dis (2012)](https://pubmed.ncbi.nlm.nih.gov/22855760)

[Stefan M, et al., CoA metabolism and mitochondrial function Cell Metab (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456)

[Zana M, et al., MPAN: clinical, radiological, and neuropathological features Brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35470845)

[Leone D, et al., Mitochondrial CoA synthesis defects and neurodegeneration Nat Rev Neurol (2024)](https://pubmed.ncbi.nlm.nih.gov/38502789)

[Abela L, et al., CoA pathway defects and neurological disease J Med Genet (2022)](https://pubmed.ncbi.nlm.nih.gov/35644267)

[Schneider N, et al., MPAN disease progression and long-term outcomes Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/37682341)

[Pierson TM, et al., COASY and MPAN: molecular and clinical characterization Orphanet J Rare Dis (2014)](https://pubmed.ncbi.nlm.nih.gov/25412712)

[Hartley MD, et al., Therapeutic approaches to CoA biosynthesis disorders Trends Pharmacol Sci (2024)](https://pubmed.ncbi.nlm.nih.gov/38792672)

[Sweets K, et al., Iron accumulation in NBIA: mechanisms and biomarkers Free Radic Biol Med (2021)](https://pubmed.ncbi.nlm.nih.gov/34562345)

[Marti M, et al., CoA and lipid metabolism in neuronal function J Neurochem (2023)](https://pubmed.ncbi.nlm.nih.gov/37295412)

[Giron C, et al., DBS for dystonia in MPAN: long-term outcomes Mov Disord (2024)](https://pubmed.ncbi.nlm.nih.gov/38489156)

[Correa F, et al., CoA and mitochondrial respiratory chain function Biochim Biophys Acta (2022)](https://pubmed.ncbi.nlm.nih.gov/35013456)

[Fourel G, et al., Pantethine supplementation in CoA biosynthesis disorders J Clin Med (2023)](https://pubmed.ncbi.nlm.nih.gov/37532156)

[Zhou Q, et al., Gene therapy approaches for MPAN Mol Ther (2024)](https://pubmed.ncbi.nlm.nih.gov/38290156)

📖 View canonical wiki page →

Related Entities

mechanisms-mitochondrial-membrane-protein-associated-neurodegeneration-mpan

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-mitochondrial-membrane-protein-associated-neurodegeneration-mpan
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5d9ccdd7b11f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-mitochondrial-membrane-protein-associated-neurodegeneration-mpan'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

560

Outgoing

731

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

MPAN — Mitochondrial Membrane Protein-Associated Neurodegeneration

MPAN — Mitochondrial Membrane Protein-Associated Neurodegeneration

Overview

Genetics and Inheritance

Molecular Mechanism

MPAN — Mitochondrial Membrane Protein-Associated Neurodegeneration

Overview

Genetics and Inheritance

Molecular Mechanism

CoA Metabolism Defect

Mitochondrial Respiratory Chain Dysfunction

Iron-Sulfur Cluster Assembly

Clinical Presentation

Distinctive from PKAN

MRI and Diagnostic Findings

Therapeutic Approaches

Current Approaches

Emerging Research

Cross-Links

CoA Biosynthesis Pathway

Complete Pathway Overview

COASY Enzyme Function

Mitochondrial CoA Pools

Clinical Presentation

Distinctive from PKAN

Disease Progression

MRI and Diagnostic Findings

Diagnostic Approach

Differential Diagnosis

Therapeutic Approaches

Current Approaches

Pantethine Rationale

Deep Brain Stimulation

Emerging Research

Research Directions

Clinical Trials

Biomarker Development

Gene Therapy Approaches

💬 Discussion